Falcon Point Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Falcon Point Capital’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-81,223	Closed	-$2.7M	–	110
2018 Q4	$2.7M	Sell	81,223 -107,118	-57%	-$4.61M	1.61%	25
2018 Q3	$9.48M	Buy	188,341 +112,989	+150%	+$5.58M	2.04%	19
2018 Q2	$4.51M	Sell	75,352 -194,152	-72%	-$10.1M	0.89%	47
2018 Q1	$12.3M	Sell	269,504 -47,202	-15%	-$1.97M	2.47%	10
2017 Q4	$12.6M	Sell	316,706 -18,953	-6%	-$749K	2.13%	19
2017 Q3	$14M	Buy	335,659 +102,995	+44%	+$4.46M	2.03%	17
2017 Q2	$10M	Sell	232,664 -255,053	-52%	-$9.08M	1.35%	36
2017 Q1	$15.3M	Sell	487,717 -19,790	-4%	-$530K	2.04%	19
2016 Q4	$12.8M	Buy	507,507 +53,505	+12%	+$1.2M	1.72%	26
2016 Q3	$8.99M	Buy	454,002 +165,910	+58%	+$3.75M	1.37%	37
2016 Q2	$5.87M	Sell	288,092 -120,387	-29%	-$2.14M	1.01%	43
2016 Q1	$6.23M	Buy	408,479 +103,876	+34%	+$1.36M	1.08%	45
2015 Q4	$4.09M	Buy	304,603 +192,148	+171%	+$2.97M	0.88%	42
2015 Q3	$1.58M	Buy	112,455 +4,677	+4%	+$87K	0.56%	56
2015 Q2	$1.83M	Buy	107,778 +85,104	+375%	+$1.21M	0.62%	50
2015 Q1	$274K	Buy	+22,674	New	+$214K	0.21%	99

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Falcon Point Capital's SUPN Position: Q1 2019 in Review

Falcon Point Capital sold out of Supernus Pharmaceuticals (SUPN) in Q1 2019, closing a stake of 81,223 shares — an estimated $2.7M sold.

Falcon Point Capital first reported a position in SUPN in Q1 2015 and held it in 16 quarters. The position peaked at $15.3M in Q1 2017. 289 funds tracked by Wall St. Rank hold SUPN as of Q1 2019.

Falcon Point Capital reported no remaining Supernus Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Falcon Point Capital sold 81,223 Supernus Pharmaceuticals shares in Q1 2019, an estimated $2.7M.
Falcon Point Capital first reported a position in Supernus Pharmaceuticals in Q1 2015 and held it in 16 quarters.
Falcon Point Capital's Supernus Pharmaceuticals position peaked at $15.3M in Q1 2017.
289 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2019.

Based on Falcon Point Capital's 13F filing for Q1 2019, filed 8 May 2019.